glp 1 research The GLP-1 revolution: What UAB researchers are discovering about how these drugs work Frontiers | GLP-1R in diabetes

Although prevalence estimates vary according to diagnostic criteria, the global prevalence of SO among adults aged 60 years and older has been reported 11% [3]

How long will it take until more options are available

Girnita is one of the first rheumatologists publicly discussing GLP-1 microdosing as an adjunctive strategy for inflammatory arthritis

In a network meta-analysis of 60 clinical trials, GLP-1 receptor agonists were associated with significant reductions in SBP (ranging from 1.84 mmHg [95% CI 3.48 to 0.20] for dulaglutide to 2.65 mmHg [95% CI 5.19 to 0.24] for albiglutide 30 mg) compared to placebo (34)

[DOI] [PubMed] [Google Scholar] 104.Moon JS, Kim NH, Na JO, Cho JH, Jeong IK, Lee SH, et al

According to FDA-approved labeling, Wegovy is indicated specifically for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, and is intended for use alongside reduced-calorie diet and increased physical activity